INTS vs IRD

Intensity Therapeutics, Inc. vs Opus Genetics, Inc. — Valuation Comparison 2026

INTS

Biotechnology
Intensity Therapeutics, Inc.
Quality
3.7
out of 10
Value Trap
12
SAFE
Price
$4.42
Last close
Models
7/13
Active
VS

IRD

Biotechnology
Opus Genetics, Inc.
Quality
5.2
out of 10
Value Trap
44
WARN
Price
$4.20
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType INTS Fair ValueINTS Upside IRD Fair ValueIRD Upside
Bayesian DCF Intrinsic $3.24 -26.8% $1.10 -73.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.26 -95.1% $0.70 -83.2%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $4.99 +12.9% $4.80 +14.3%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for INTS vs IRD — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

INTS vs IRD — Which Stock Is More Undervalued?

IRD scores higher with a 5.2/10 quality rating vs INTS's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Intensity Therapeutics, Inc. (INTS) and Opus Genetics, Inc. (IRD) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

INTS currently trades at $4.42 with a QOC of 3.7/10, while IRD trades at $4.20 with a QOC of 5.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).